Latest Conference Coverage

Rodolfo Savica, MD, PhD: Dyskinesias in Atypical Parkinsonism

The associate professor of neurology at Mayo Clinic spoke about the findings of a population-based cohort study seeking to investigate the incidence of levodopa-induced dyskinesia in atypical parkinsonism.

Rebecca Ichord, MD: Challenges in Providing Care for Pediatric Stroke

The director of the Pediatric Stroke Program at CHOP spoke about the need to improve early recognition and assessments in pediatric stroke, and how ultimately, awareness of the condition is a huge step toward achieving this goal.

Fingolimod Significantly Reduces Blood NfL in Relapsing-Remitting Multiple Sclerosis

NfL levels were reduced during treatment with fingolimod, providing further evidence of the long-term benefit of the drug and demonstrating a greater impact of highly effective therapy in relapsing-remitting multiple sclerosis.

Robert Fox, MD: Neurofilament Light and the SPRINT MS Trial

The staff neurologist at Cleveland Clinic shared his insight from the study, as well as what these data can do to further inform the use of this biomarker in progressive MS trials.

MSProDiscuss Tool Shows Signs of Validity for Clinical Use in Multiple Sclerosis

The lead investigator noted that “the study results are a promising step toward having a scientifically-validated tool for clinical use that can facilitate physician-patient conversations and ultimately help to get ahead of MS progression.”

Margaret Moline, PhD: Next-Morning Residual Effects of Lemborexant in Insomnia

The International Project Team Lead spoke about the results of study endpoints that assessed the potential for next-morning residual effects of lemborexant, which is in development for insomnia.

Evobrutinib Reduces Lesions in Patients With Relapsing MS

Evobrutinib is the first BTK inhibitor to demonstrate clinical proof of concept in multiple sclerosis, reducing Gd+ lesions in a 75-mg, once-daily dose.

Suvorexant Increases Total Sleep Time in Alzheimer Disease

Suvorexant improved the mean total sleep time by 28.2 minutes for the patients receiving the treatment versus placebo, equating to a mean increase of 73.4 minutes with the orexin receptor antagonist.

Valbenazine Data Delivers Vital View of the Impact of Tardive Dyskinesia on Patients

The chief medical officer of Neurocrine Biosciences spoke about how long-term data on valbenazine (Ingrezza) has helped shape the understanding of the effect tardive dyskinesia can have on patients, and how it can inform better utilization of the medication.

Huma Sheikh, MD: Complementary Approaches for Multimodal Migraine Treatment

The assistant professor of neurology at Mount Sinai Health System spoke about the recent trend toward approaching migraine in a more holistic fashion, and the incorporation of nonpharmacologic options for patients with the chronic headache condition.

Oral Anti-CGRP Agent Atogepant Reduces Migraine Days in Episodic Migraine

Patients across all dosing groups saw statistically significant and clinically relevant reductions in migraine days during the 12-week treatment period compared with the placebo group.

Zilucoplan Maintains Positive Efficacy for Patients With Myasthenia Gravis In Extension Period

Enough evidence to support further evaluation in a phase 3 trial in myasthenia gravis has been collected from these new phase 2 data of zilucoplan, formerly known as RA101495 SC.

Jacqueline French, MD: Dangers of Delayed Diagnosis in Epilepsy

The director of Translational Research and Epilepsy Clinical Trials at NYU Langone spoke about the nuance involved in diagnosing epilepsy and the misconceptions about how seizures present in the majority of patients.

Ozanimod Reduces Grey Matter Loss in Relapsing Multiple Sclerosis

Compared to interferon beta-1a, the reduction of grey matter volume loss was greater in those treated with both doses of the oral S1P receptor modulator across all age groups, including the youngest patients at the highest risk for brain volume loss.

Alexander Kolevzon, MD: The STARS Study in Angelman Syndrome

The director of Child and Adolescent Psychiatry at Mount Sinai Health System spoke about the results of the phase 2 study of OV101 (gaboxadol), and the next steps for the phase 3 trial.

Investigational Huntington Disease Therapy Shows Promising Results

The investigators observed a dose-dependent reduction of mutant huntingtin concentration in the cerebrospinal fluid of patients who received HTTRX, supporting the launch of a confirmatory phase 3 trial.

Jessica Robinson-Papp, MD: Medical Marijuana for Neurologic Conditions

The professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.

CX-8998 Exhibits Promise in Essential Tremor Despite Failing to Meet Primary End Point

Although the primary end point of centrally video-rated TETRAS Performance Subscale did not achieve statistical significance, CX-8998-treated patients showed significant improvements in a number of other measurements.

Amit Rakhit, MD, MBA: Developing Therapies for Fragile X Syndrome

The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about the Visual Analog Scale that the company developed to help better understand the impact that potential treatments have on patients with Fragile X syndrome.

Galcanezumab Significantly Reduces Weekly Cluster Headache Attacks

The anti-CGRP drug, which was recently approved for the prevention of migraine in adults, showed significant reductions in weekly cluster headache attack frequency by week 3 in 76% of patients.

Orally Dissolving Rimegepant Rapidly Lowers Pain, Improves Symptoms for Acute Migraine

A 75 mg orally dissolving tablet formulation of the calcitonin gene-related peptide receptor antagonist met both co-primary end points of freedom from the patient-indicated most bothersome symptom and freedom from pain at 2 hours.

Fingolimod Reduces ARR in Patients With MS Who Switch From Other DMTs

The sphingosine1-phosphate receptor modulator was shown to annualize relapse rates by more than 70% for patients switching from other disease-modifying therapies such as dimethyl fumarate; teriflunomide, and daclizumab.

CBD Has Potential for a Variety of Epilepsy Conditions, Expert Says

The medical director of neurology and co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital spoke about what CBD has shown in clinical trials and how it could make an impact outside of Lennox-Gastaut and Dravet syndromes.

Eculizumab Significantly Reduces Relapse Risk in Neuromyelitis Optica Spectrum Disorder

The treatment was efficacious in patients with AQP4-IgG-positive NMOSD, which accounts for nearly three-quarters of the population with the disorder, for which there is currently no approved treatment.

Robert Fox, MD: Combining the Symbol Digit Modalities Test and EDSS in Progressive MS

The Cleveland Clinic neurologist explained how the combination of the SDMT and EDSS measurements could improve the phase 3 clinical trial landscape in multiple sclerosis.

New Guideline for Tourette Syndrome, Tic Disorders Emphasizes Behavioral Therapy as First-Line Intervention

The guideline, which is endorsed by the Child Neurology Society and the European Academy of Neurology, is the first guideline on the topic for US-based clinicians.

Gaboxadol Shows Clinical Benefit in Angelman Syndrome in Phase 2 Study

The phase 2 STARS trial was the first time in 50 years that an overall improvement in patients with Angelman syndrome was observed, in this instance with a once-daily dose of gaboxadol, also known as OV101.

Jacqueline French, MD: Inhaled Alprazolam for Aborting Predictable Seizure Episodes in Epilepsy

The professor of neurology and director of translational research and epilepsy clinical trials at NYU Langone spoke about the results of a phase 2b open-label feasibility study of this novel delivery method for abortive seizure treatment in patients with epilepsy.

Gene Therapy Zolgensma Displays Efficacy in SMA Across Spectrum of Patients

In a pair of phase 2 trials and a phase 1 study, patients with SMA types 1 and 2 treated with the gene therapy displayed a number of motor milestone achievements and a prolonged event-free survival rate.

Inhaled Alprazolam Promising as Abortive Seizure Treatment

Results from the phase 2b study in 8 patients with predictable seizure patterns demonstrated good feasibility, tolerability, and efficacy, with a 62.5% responder rate.